Serological, molecular and clinicopathological findings associated with Leishmania infantum infection in cats in Northern Italy

(Article begins on next page)

24 April 2024

Original Article

Serological, molecular and clinicopathological findings associated with *Leishmania infantum* infection in cats in Northern Italy

Lorenza Urbani[*], Alessandro Tirolo[*], Daniela Salvatore, Michele Tumbarello, Sofia Segatore, Mara Battilani, Andrea Balboni, Francesco Dondi.

Department of Veterinary Medical Sciences, Alma Mater Studiorum–University of Bologna, Ozzano dell'Emilia, Bologna, Italy

*These authors contributed equally

Corresponding author:

Francesco Dondi DVM, PhD, Department of Verinary Medical Sciences, Alma Mater Studiorum–University of Bologna, Via Tolara di Sopra 50, Ozzano dell'Emilia, Bologna 40064, Italy

Email: f.dondi@unibo.it

Abstract

Objectives To investigate the prevalence of *Leishmania* species infection in cats in Northern Italy and to evaluate the associations between infection, and signalment and clinicopathological data.

Methods The study was carried out in a veterinary university hospital from June to November 2017. Blood, urine, conjunctival swabs and hair were collected from all cats which had been randomly selected. *Leishmania* species infection was evaluated using the indirect fluorescent antibody test (IFAT), setting a cut-off value of 1:80 and real-time PCR on blood, conjunctival and hair samples. A complete blood count, serum chemistry profile, serum electrophoresis and urinalysis were also carried out. The cats were grouped on the basis of the results of the diagnostic criteria adopted in positive, negative and unconfirmed *Leishmania* cases. Non-parametric variables and continuous data were compared among the study groups using the χ^2 test and the Mann–Whitney U-test, respectively.

Results One hundred and fifty-two cats were included. Nineteen of the 152 (12.5%) cats were positive: 18/152 (11.8%) showed IFAT titre ≥1:80 and 1/152 (0.7%) was real-time PCR-positive in a hair sample; 106/152 (69.7%) cats were negative, and 27/152 (17.8%) cats were unconfirmed for *Leishmania*. Total proteins, beta$_2$-globulin and gamma-globulin were significantly increased in the positive *Leishmania* group when compared to the negative group.

54 **Conclusions and relevance** The results of the present study demonstrated the spread of

55 *L infantum* infection in cats in Northern Italy. Hyperprotidaemia and

56 hypergammaglobulinaemia appeared to be significant clinicopathological abnormalities

57 in this population of cats with *L infantum* infection.

58   **Keywords:** feline leishmaniosis; indirect immunofluorescence test; real-time PCR;

59   clinicopathological abnormalities

Introduction

To date, in Italy, canine leishmaniosis (CanL) is considered to be endemic throughout most of the national territory having a variable prevalence. Recent studies have detected *Leishmania* species infection in domestic cats as well in areas where CanL is endemic,[1] with seroprevalence ranging from 0 to 68.5% and molecular prevalence ranging from 0 to 60.7%.[2] Cats have a neglected and controversial role in the cycle of *L infantum*[3] but whether they serve as primary, secondary or accidental hosts is currently unknown.[4] Furthermore, only a few studies have been carried out regarding clinical and clinicopathological abnormalities in cats with feline leishmaniosis (FeL).[2]

The majority of the diagnostic techniques for *Leishmania* species infection available for dogs are also employed for cats. The most common serological test used is the indirect fluorescent antibody test (IFAT).[2,4-7] Of the molecular methods, the real-time PCR (qPCR) allows quantitative and fast detection of *Leishmania* species DNA.[8,9] Detection using DNA can be applied to a variety of biological matrices, including bone marrow, skin biopsy and lymph node aspirate. These samples are difficult to obtain and, in some cases, sedation of the animal is required.[2,10] Little is still known regarding the use of non-invasive biological matrices for the molecular detection of *Leishmania* species DNA in cats, such as peripheral blood, conjunctival swabs and hair.[6,11-13]

The aims of this study were (a) to investigate the presence and diffusion of *Leishmania* species infection in cats in Northern Italy using IFAT and qPCR assays applied to

different biological samples (serum, blood, conjunctival swabs and hair) and (b) to

evaluate possible associations between infection by *L infantum* and signalment and

clinicopathological data.

Materials and Methods

Study design, inclusion criteria, sampling and groups

This was a prospective study carried out in a veterinary university hospital in Northern

Italy (Department of Veterinary Medical Science, University of Bologna). Client-owned

cats were included in the study during the sandfly activity season (from June to

November 2017) after random selection and owner consent. Cats were included if they

had the following requisites: (1) living in the Emilia-Romagna region and (2) had

undergone a blood sample after clinical examination. Signalment, lifestyle (indoor or

outdoor) and clinical data were recorded for each cat sampled.

Blood sampling was carried out by venepuncture, and samples were collected using a

vacuum system (Vacutest Kima). The K_3EDTA samples were used for a complete blood

count (CBC) and molecular analyses. Serum samples underwent a chemistry profile and

serum protein electrophoresis. The urine samples were collected by spontaneous

voiding, cystocentesis or urethral catheterisation, when required, by the attending

clinicians, and underwent urinalysis. Conjunctival swabs from both eyes and hair

(pulling) samples were also collected from each cat. Clinicopathological evaluation was

100 carried out within 1 h from the sampling and the samples were stored at –80°C after

101 examination. *Leishmania* species infection was investigated using IFAT and qPCR on

102 serum and blood, conjunctival swabs and hair samples, respectively.

103 Cats with a positive IFAT titre (≥1:80)[14] and/or positive qPCR on blood and/or

104 conjunctival swabs and/or hair samples were included in the positive *Leishmania* (PL)

105 group; cats with a negative IFAT titre (<1:40) and negative qPCR results were included

106 in the negative *Leishmania* (NL) group; cats with a IFAT titre equal to 1:40 and

107 negative qPCR results were included in the unconfirmed *Leishmania* (UL) group.

108 Moreover, the medical records of the PL group were analysed to evaluate signalment,

109 history, and clinical and clinicopathological data.

110 **Indirect fluorescent antibody test**

111 Anti-*Leishmania* IgG antibodies were investigated in serum samples using IFAT

112 according to the CanL diagnosis described in the World Organisation for Animal Health

113 (OIE) manual of diagnostic tests and vaccines for terrestrial animals.[15] Slides coated

114 with 30 µl of an in-house antigen consisting of promastigotes of *L infantum* (strain

115 MHOM/TN/80/IPT1)[16] were probed with sera serially diluted in phosphate-buffered

116 saline (PBS) starting with a concentration of 1:40 until reaching a concentration of

117 1:5120, incubated for 30 mins at 37°C and washed three times with PBS. Internal feline

118 positive (1:160) and negative sera controls were included on each slide. The slides were

119 probed with 30 µl fluorescein isothiocyanate (FITC) conjugated anti-cat IgG antibody

120   diluted in PBS at a concentration of 1:32 (Anti-Cat IgG-FITC antibody; Sigma-Aldrich)

121   for 30 mins at 37°C, were washed three times with PBS, and examined under the

122   fluorescent microscope. The highest dilution showing fluorescent promastigotes was the

123   final antibody titre.

124   **Molecular diagnosis**

125   Genomic DNA was extracted from blood, conjunctival swabs and hair samples using a

126   commercially available kit (NucleoSpin Tissue Kit; Macherey-Nagel) according to the

127   manufacturer's protocol. Before extraction, for each cat sampled, the two conjunctival

128   swab samples (right and left eyes) were resuspended together in 250 µl of PBS. Instead,

129   the hair samples were cut into three segments (proximal, central and distal) and lysed at

130   56°C overnight with 250 µl of lysis buffer (Buffer T1) and 50 µl of proteinase K

131   supplied in the extraction kit.

132   *Leishmania* species DNA detection was carried out using SYBR Green qPCR as

133   reported by Ceccarelli and collaborators.[17] A reaction was carried out using a

134   commercially available kit (PowerUp SYBR Green Master Mix Kit, Life Technologies)

135   and the StepOnePlus Real-Time PCR System (Thermo Fisher Scientific, Life

136   Technologies). Serial 10-fold dilutions of a plasmid (pCR4 plasmid; Invitrogen; Life

137   Technologies) containing one copy of the target sequence was used as an external

138   standard for the construction of the assay standard curve. Melting experiments were

139   carried out after the last extension step with a continuous increment from 60 to 95°C;

140   the specific melting temperature (T*m*) was 80.7°C. The limit of detection (LOD) of the

141   assay was assessed by testing serial 10-fold dilutions of the recombinant plasmid and

142   was found to be 1 x 10^0 copy/µl. The DNA samples and standards were repeated within

143   each run in duplicate. A no template control underwent analysis simultaneously. The

144   specimens were considered positive if the fluorescence curve in the amplification plot

145   showed an exponential increase, a specific melting peak was observed and the mean of

146   the DNA copy number obtained from the replicates was greater than the LOD.

147   **Clinicopathological investigations**

148   A CBC was carried out using an automated haematology analyser (ADVIA 2120;

149   Siemens Healthcare Diagnostics). The haematology was completed with a microscopic

150   blood smear examination using May-Grünwald Giemsa staining. A serum chemistry

151   profile, including creatinine, urea, phosphate, total protein, albumin, the albumin to

152   globulin ratio (A:G), alanine transaminase, aspartate transaminase, alkaline

153   phosphatase, gamma(γ)-glutamyltransferase, total bilirubin, cholesterol, total calcium,

154   sodium, potassium, chloride, glucose, and serum amyloid A (SAA), as reported

155   previously,[18] was determined. Urinalysis included urine specific gravity (USG), dipstick

156   (Combur[10]TestUX; Roche) and microscopic sediment examination, and the urine

157   protein:creatinine ratio (UPC). Urine samples with a visible red colour and/or >250 red

158   blood cells (RBCs) in a high power field (hpf) were excluded from the UPC analysis.

159   Serum and urine chemical analysis were carried out using an automated analyser

160   (AU480; Beckman Coulter-Olympus).

161   Serum protein electrophoresis was carried out on agarose gel using a semi-automated

162   system (Hydragel protein kit; Hydrasys; Sebia).

163   **Statistical analysis**

164   The data were evaluated using standard descriptive statistics and reported as mean ±

165   standard deviation or median and range (min–max), based on their distribution. The cats

166   included in the UL group were excluded from all analyses. The categorical data were

167   analysed using the χ2 test. The upper limits of the reference interval used in the

168   university lab for cats were used as cut-off values for hyperproteinaemia and

169   hypergammaglobulinaemia and were 8.8 g/dl and 1.30 g/dl, respectively. The

170   continuous data (age and clinicopathological results) were compared among the study

171   groups using the Mann–Whitney U-test with compensated post-hoc analysis. A *P* value

172   <0.05 was considered significant. An inter-rater agreement statistic (Cohen's kappa

173   coefficient) was calculated to compare the results obtained by IFAT and qPCR, and

174   between the qPCR carried out on three different biological samples. Statistical analysis

175   was carried out using commercially available software (MedCalc Statistical Software

176   version 16.8.4).

177

178   **Results**

Study groups and diagnosis of *L infantum* infection

During the study period, 152 cats met the inclusion criteria. Nineteen of the 152 (12.5%) cats were included in the PL group: 18/152 (11.8%) showed IFAT titre ≥1:80 and 1/152 (0.7%) was tested qPCR-positive in hair sample. The NL group included 106/152 (69.7%) cats and the UL group included 27/152 (17.8%). Table 1 shows the descriptive statistics results and data regarding the prevalence of infection in the study population.

Thirteen of the 19 (68.4%) cats included in the PL group were male of which 12/13 (92.3%) were castrated, and 6/19 (31.6%) were female of which 5/6 (83.3%) were spayed. Seventeen of the 19 (89.5%) were more than 24 months of age and 2/19 (10.5%) were between 6 and 24 months of age, with a median age of 8 years (9 months-15 years). Fourteen of the 19 (73.7%) were European domestic shorthair cats and 5/19 (26.3%) were from other various breeds (Maine Coon = 1; Bengal = 1; Birman = 1; Persian = 1; Chartreux = 1); 12/19 cats (63.2%) were indoor/outdoor while 7/19 (36.8%) were exclusively indoor. Sixteen of the 19 (84.2%) cats were from the province of Bologna. The highest frequency of positivity was detected in July (5/35; 14.3%) and August (7/22; 31.8%) while the frequency decreased in the other months of sampling.

Seroreactivity (IFAT titre ≥1:40) to *L infantum* was found in 45 of the 152 (29.6%) cats tested. Of the 18 seropositive cats (IFAT titre ≥1:80), 11 (61.1%) had an antibody titre equal to 1:80, five (27.8%) 1:160 and two (11.1%) 1:320 (Tables 2 and 3).

199 The cat identified as positive on hair using qPCR showed 8 copies of *Leishmania*

200 kinetoplast DNA/µl of DNA extract and was seronegative to *L infantum* (Table 2). This

201 cat was a 10-year-old European domestic shorthair castrated male which lived indoors

202 and was sampled in August.

203 Forty-nine of the 106 cats included in the NL group were male of which 43/49 (87.8%)

204 were castrated while the remaining 57 were female of which 45/57 (78.9%) were

205 spayed. Ninety-two (86.8%) were more than 24 months old, with a median of 7 years (4

206 months–20 years); 92/106 (86.8%) were European domestic shorthair cats and 93/106

207 (87.7%) were from the province of Bologna. Forty-nine of the 106 (46.2%) were indoor

208 cats and 47/106 (44.3%) were indoor/outdoor cats.

209 No statistical association was found among positivity to *L infantum* and sex, age, breed,

210 geographical origin, access to outdoor environment and month of sampling. Although

211 not significant, an increased frequency in positivity among cats sampled in July and

212 August was observed ($P = 0.071$) (Table 1).

213 No agreement between the results obtained by IFAT and qPCR and between the qPCR

214 carried out on three different biological samples was shown by the value of Cohen's

215 kappa coefficient ($P = 0.309$).

216 **Clinical and clinicopathological findings**

217 The results of the CBC, serum chemistry, protein electrophoresis, and urinalysis

218 including UPC obtained in the PL and NL groups are shown in Table 4. Total proteins,

13

219   beta(β)$_2$-globulin and gamma(γ)-globulin fractions were significantly increased in the

220   PL group (Table 4). Hyperproteinaemia and hypergammaglobulinaemia were detected

221   in 3/19 (15.8%) and 11/19 (25.6%) PL cats, respectively. The frequency of

222   hyperproteinaemia and hypergammaglobulinaemia were significantly increased in the

223   PL group when compared to the NL group ($P = 0.028$ and $P = 0.038$, respectively). No

224   other significant differences among the groups selected were detected.

225   No clinical signs associated with leishmaniosis were observed in any cat included in this

226   study, and leishmaniosis was never suspected by the attending clinicians. In the PL

227   group, cats with antibody titre equal to 1:80 (11/18) had gastroenteritis (n = 6),

228   neurological disorders (n = 1) and chronic kidney disease (CKD) (n = 2). Moreover,

229   2/11 in the PL group tested positive for feline *calicivirus* (FCV) and 1/11 for feline

230   immunodeficiency virus. Cats with an antibody titre greater than 1:80 (7/18) had more

231   severe diseases including autoimmune thrombocytopenia (n = 1), hypertrophic

232   cardiomyopathy (n = 1), hyperthyroidism (n = 2), neoplastia (n = 2), CKD (n = 3) and

233   Addison's disease (n = 1). One out of the seven presented coinfection with feline

234   herpesvirus and FCV, and was treated with glucocorticoids. The only cat identified

235   positive by qPCR was affected by CKD.

236   Six months after serological and molecular positivity, 8/19 (42.1%) cats included in the

237   PL group died from causes not apparently attributable to leishmaniosis. Two of them

238   had an IFAT titre of 1:80 upon admission, four had 1:160 and one had 1:320. The

239 qPCR-positive cat was euthanised within six months after inclusion in the study due to

240 CKD progression.

241

242 **Discussion**

243 The primary aim of this study was to investigate the prevalence of *Leishmania* species

244 infection in cats in Northern Italy, an area which is becoming endemic for CanL. The

245 secondary aim was to determine whether there was an association between *L infantum*

246 positivity, and signalment and clinicopathological data.

247 Two different diagnostic methods, IFAT and qPCR, were used to evaluate the presence

248 of *Leishmania* species infection in cats, and the overall prevalence detected was 12.5%.

249 Recent studies carried out in Italy have reported a similar (12.2%) or a greater (25.8%)

250 prevalence of infection.[5,6] In the present survey, the use of a molecular test allowed the

251 identification of infected subject which had not developed a detectable antibody

252 response, suggesting that serology may underestimate the real number of infected

253 animals.[19]

254 No standardised IFAT assay for the detection of antibodies against *Leishmania* species

255 is currently available for cats, and an antibody titre value universally accepted as

256 indicative of active infection has not been identified.[20] In the present study,

257 seroreactivity (≥1:40) to *L infantum* was found in 29.6% of the cats tested. Other studies

258 have reported seroreactivity ranging from 16.3 to 30% in Italy.[5,21] However, positivity

259   with a 1:40 titre is not indicative of infection; therefore, the seroprevalence could be

260   overestimated using lower cut-offs.[4,14] Based on the cut-off value ≥1:80,[2,4,14] the

261   seroprevalence detected decreases to 11.8%. Similar results have been reported in

262   Northern Italy by Spada and colleagues,[5] suggesting the spread of feline infection in

263   recent years. In the present study, *L infantum* DNA was only identified in the hair

264   sample of one cat. *L infantum* DNA was not detected in any of the blood and

265   conjunctival swab samples, even in seropositive cats. The possible reasons for the

266   inconsistency of DNA detection in blood is the absence of parasitaemia in cats except in

267   case of severe disease or intermittent parasitaemia as described in dogs.[22,23]

268   Nevertheless, higher and variable values of molecular prevalence of *L infantum*

269   infection assessed by testing feline blood and conjunctival samples have been reported

270   in Italy;[5,6,11,13,24] and in other European countries.[12,19,25-28] These results suggest that

271   future molecular studies should be carried out to evaluate the diagnostic accuracy of

272   non-invasive samples in cats as has already been done in dogs.

273   In the present study, *L infantum* DNA was detected in the hair of one cat, confirming

274   the possible utility of this biological sample for the diagnosis of FeL as has been

275   reported for CanL.[29] The negative result obtained in the IFAT carried out on this cat

276   could reflect an ineffective immune system response or could be explained by the

277   absence of antibody production during an early stage of the infection.[25] Discordant

278 findings between the serological testing and molecular methods have also been reported

279 previously.[20,30-33]

280 No significant association was found between *L infantum* infection and signalment data

281 as has been reported in previous studies.[5,25,33,34] An interesting finding of the present

282 study, although not sustained by statistical significance, is the increased prevalence of

283 infection in the cats sampled in July and August, probably due to the increased

284 phlebotomus activity in Southern Europe during these months.[35]

285 Positivity to *L infantum* in cats was associated with a significant increase in total

286 proteins, β_2 and γ globulins and with a decrease in the A:G, although not significant

287 when compared to the negative cases. Interestingly, 15.8% and 25.6% of the PL group

288 had hyperproteinaemia and hypergammaglobulinaemia, respectively, and the frequency

289 of these abnormalities was significantly increased when compared to the NL group.

290 Hyperproteinaemia associated with hyperglobulinaemia has been commonly found in

291 FeL,[4,36,37,38] and, in a study carried out on four cats, hyperglobulinaemia was classified

292 as hypergammaglobulinaemia.[36] However, the presence of hyperproteinaemia,

293 decreased the A:G, and polyclonal β and γ hyperglobulinaemia have long been reported

294 in the course of CanL.[39] Therefore, it can be hypothesised that in cats, as in dogs, the

295 humoral immune response could also be activated by the production of

296 immunoglobulins after infection. When FeL is suspected in a feline patient, performing

297 serum electrophoresis can be recommended to support the diagnosis by means of

298 evidence of β_2 and γ polyclonal hyperglobulinaemia.

299 No other significant difference was found in the haematological and serum chemistry

300 variables between the two groups studied, although mild to severe non-regenerative

301 normocytic anaemia, thrombocytopenia, leukopenia, pancytopenia and

302 hypoalbuminemia increased liver enzyme activity, and serum creatinine and urea

303 concentrations have been the most frequent abnormalities previously reported in clinical

304 cases of FeL.[2,4,36-38,40] Proteinuria is often the only abnormal clinicopathological finding

305 in dogs with CanL[39] whereas it has been described only occasionally in cats with

306 FeL.[4,36,41] In this study, an increase in the UPC in the PL group was not observed as

307 compared to the NL group. These results could be explained by the composition of the

308 NL group. In fact, the NL group was not composed of healthy cats, but also included

309 patients suffering from other diseases not related to *L infantum* infection, including

310 numerous cats suffering from renal disease which can be accompanied by several

311 laboratory abnormalities.

312 The clinical cases of feline leishmaniosis reported have frequently been associated with

313 skin lesions as well as other less specific clinical signs.[30,34] None of the positive cats

314 included in this study showed clinical signs of leishmaniosis, and the disease had never

315 been suspected by the attending clinicians. This suggests that subclinical feline

316   infections could be common in areas which are becoming endemic for CanL and that

317   clinical illness due to *L infantum* in cats is currently rare.[2]

318   Some limitations should be acknowledged when interpreting the present results.

319   Sampling should have lasted for more than a year, and the number of cats sampled

320   within the inclusion period should have been more homogeneous in each month. A

321   second staggered sampling would have been necessary for the cats included in the UL

322   group to assess the changes in the antibody response. Moreover, the study population

323   consisted mainly of cats referred to a veterinary hospital and, consequently, the animals

324   included in the study could have presented clinicopathological abnormalities not related

325   to *L infantum* infection, affecting the comparison between the PL and NL groups.

326

327   **Conclusions**

328   The results of the present study suggested the spread of *L infantum* infection in cats in

329   Northern Italy, although in the majority of cases, the infection did not seem to lead to

330   active disease. The use of a molecular technique for the detection of the *Leishmania*

331   species does not replace the serology but may support the final diagnosis.

332   Hyperproteinaemia and hypergammaglobulinaemia appeared to be significant

333   clinicopathological abnormalities in cats with *Leishmania* species infection. Additional

334   studies are needed to better assess the role of cats in the epidemiological cycle of

335   *Leishmania* species and the pathogenic role of *L. infantum* in this host.

References

356

357 1   Metzdorf IP, da Costa Lima-Junior MS, de Fatima Cepa Matos M, et al. **Molecular**

358   **characterization of *Leishmania infantum* in domestic cats in a region of Brazil**

359   **endemic for human and canine visceral leishmaniasis.** *Acta Trop* 2017; 166:

360   121–125.

361 2   Pennisi MG, Cardoso L, Baneth G, et al. **LeishVet update and recommendations**

362   **on feline leishmaniosis.** *Parasit Vectors* 2015; 8: 302.

363 3   Pennisi MG. **Leishmaniosis of companion animals in Europe: an update.** *Vet*

364   *Parasitol* 2015; 208: 35–47.

365 4   Pennisi MG and Persichetti MF. **Feline leishmaniosis: Is the cat a small dog?** *Vet*

366   *Parasitol* 2018; 251: 131–137.

367 5   Spada E, Canzi I, Baggiani L, et al. **Prevalence of *Leishmania infantum* and co-**

368   **infections in stray cats in northern Italy.** *Comp Immunol Microbiol Infect*

369   *Dis* 2016; 45: 53–58.

370 6   Otranto D, Napoli E, Latrofa MS, et al. **Feline and canine leishmaniosis and other**

371   **vector-borne diseases in the Aeolian Islands: Pathogen and vector circulation**

372   **in a confined environment.** *Vet Parasitol* 2017; 236: 144–151.

373 7   Dedola C, Zobba R, Varcasia A, et al. **Serological and molecular detection of**

374   ***Leishmania infantum* in cats of northern Sardinia, Italy.** *Vet Parasitol Reg Stud*

375   *Reports* 2018; 13: 120–123.

376 8   Francino O, Altet L, Sanchez-Robert E, et al. **Advantages of real-time PCR assay**

377   **for diagnosis and monitoring of canine leishmaniosis.** *Vet Parasitol* 2006; 137:

378   214–221.

379 9   Benassi JC, Benvenga GU, Ferreira HL, et al. **Detection of *Leishmania infantum***

380   **DNA in conjunctival swabs of cats by quantitative real-time PCR.** *Exp*

381   *Parasitol* 2017; 177: 93–97.

382 10 Braga ARC, Langoni H and Lucheis SB. **Evaluation of canine and feline**

383   **leishmaniasis by the association of blood culture, immunofluorescent antibody**

384   **test and polymerase chain reaction.** *J Venom Anim Toxins Incl Trop Dis* 2014; 20:

385   5.

386 11 Pennisi MG, Lupo T, Malara D, et al. **Serological and molecular prevalence of**

387   ***Leishmania infantum* infection in cats from southern Italy.** *J Feline Med*

388   *Surg* 2012; 14: 656–657.

389 12 Chatzis MK, Andreadou M, Leontides L, et al. **Cytological and molecular**

390   **detection of *Leishmania infantum* in different tissues of clinically normal and**

391   **sick cats.** *Vet Parasitol* 2014; 202: 217–225.

392 13 Persichetti MF, Pennisi MG, Vullo A, et al. **Clinical evaluation of outdoor cats**

393   **exposed to ectoparasites and associated risk for vector-borne infections in**

394   **southern Italy.** *Parasit Vectors* 2018; 11: 136.

395   14 Persichetti MF, Solano-Gallego L, Vullo A, et al. **Diagnostic performance of**

396   **ELISA, IFAT and Western blot for the detection of anti-*Leishmania infantum***

397   **antibodies in cats using a Bayesian analysis without a gold standard**. *Parasit*

398   *Vectors* 2017; 10: 119.

399   15 World Organisation for Animal Health (OIE). **Manual of Diagnostic Tests and**

400   **Vaccines for Terrestrial Animals.** 2008, pp 240–250.

401   16 Baldelli R, Piva S, Salvatore D, et al. **Canine leishmaniasis surveillance in a**

402   **northern Italy kennel.** *Vet Parasitol* 2011; 179: 57–61.

403   17 Ceccarelli M, Galluzzi L, Migliazzo A. et al. **Detection and characterization of**

404   *Leishmania* (*Leishmania*) **and** *Leishmania* (*Viannia*) **by SYBR green-based real-**

405   **time PCR and high resolution melt analysis targeting kinetoplast minicircle**

406   **DNA.** *PLoS One* 2014; 9: e88845.

407   18 Troìa R, Balboni A, Zamagni S, et al. **Prospective evaluation of rapid point-of-**

408   **care tests for the diagnosis of acute leptospirosis in dogs.** *Veterinary J* 2018; 237:

409   37–42.

410   19 Maia C, Gomes J, Cristóvão J, et al. **Feline *Leishmania* infection in a canine**

411   **leishmaniasis endemic region, Portugal.** *Vet Parasitol* 2010; 174: 336–340.

412   20 Spada E, Proverbio D, Migliazzo A, et al. **Serological and molecular evaluation of**

413   *Leishmania infantum* **infection in stray cats in a nonendemic area in northern**

414   **Italy.** *ISRN Parasitol* 2013; 2013:916376.

415   21 Vita S, Santori D, Aguzzi I, et al. **Feline leishmaniasis and ehrlichiosis:**

416   **serological investigation in Abruzzo region.** *Vet Res Commun* 2005; 29: 319–321.

417   22 Manna L, Vitale F, Reale S, et al. **Comparison of different tissue sampling for**

418   **PCR-based diagnosis and follow-up of canine visceral leishmaniosis.** *Vet*

419   *Parasitol* 2004; 125: 251–262.

420   23 Manna L, Gravino AE, Picillo E, et al. ***Leishmania* DNA quantification by real-**

421   **time PCR in naturally infected dogs treated with miltefosine.** *Ann N Y Acad*

422   *Sci* 2008; 1149: 358–360.

423   24 Persichetti MF, Solano-Gallego L, Serrano L, et al. **Detection of vector-borne**

424   **pathogens in cats and their ectoparasites in southern Italy.** *Parasit*

425   *Vectors* 2016; 9: 247.

426   25 Ayllon T, Tesouro MA, Amusategui I, et al. **Serologic and molecular evaluation**

427   **of *Leishmania infantum* in cats from central Spain.** *Ann N Y Acad Sci* 2008;

428   1149: 361–364.

429   26 Sherry K, Miró G, Trotta M, et al. **A serological and molecular study of**

430   ***Leishmania infantum* infection in cats from the Island of Ibiza (Spain).** *Vector*

431   *Borne Zoonotic Dis* 2011; 11: 239–245.

432   27 Vilhena H, Martinez-Díaz VL, Cardoso L, et al. **Feline vector-borne pathogens in**

433   **the north and centre of Portugal.** *Parasit Vectors* 2013; 6: 99.

434 28 Akhtardanesh B, Sharifi I, Mohammadi A, et al. **Feline visceral leishmaniasis in**

435   **Kerman, southeast of Iran: Serological and molecular study.** *J Vector Borne*

436   *Dis* 2017; 54: 96–102.

437 29 Belinchón-Lorenzo S, Iniesta V, Parejo JC, et al. **Detection of *Leishmania***

438   ***infantum* kinetoplast minicircle DNA by real time PCR in hair of dogs with**

439   **leishmaniosis.** *Vet Parasitol* 2013; 192: 43–50.

440 30 Miró G, Rupérez C, Checa R, et al. **Current status of *L. infantum* infection in**

441   **stray cats in the Madrid region (Spain): implications for the recent outbreak of**

442   **human leishmaniosis?** *Parasit Vectors* 2014; 7: 112.

443 31 Silaghi C, Knaus M, Rapti D, et al. **Survey of *Toxoplasma gondii* and *Neospora***

444   ***caninum*, haemotropic mycoplasmas and other arthropod-borne pathogens in**

445   **cats from Albania.** *Parasit Vectors* 2014; 7: 62.

446 32 Attipa C, Papasouliotis K, Solano-Gallego L, et al. **Prevalence study and risk**

447   **factor analysis of selected bacterial, protozoal and viral, including vector-**

448   **borne, pathogens in cats from Cyprus.** *Parasit Vectors* 2017; 10: 130.

449 33 Montoya A, García M, Gálvez R, et al. **Implications of zoonotic and vector-borne**

450   **parasites to free-roaming cats in central Spain.** *Vet Parasitol* 2018; 251: 125–

451   130.

452 34 Sobrinho LSV, Rossi CN, Vides JP, et al. **Coinfection of *Leishmania chagasi* with**

453   ***Toxoplasma gondii*, Feline Immunodeficiency Virus (FIV) and Feline Leukemia**

454   **Virus (FeLV) in cats from an endemic area of zoonotic visceral**

455   **leishmaniasis.** *Vet Parasitol* 2012; 187: 302–306.

456   35 Gaglio G, Brianti E, Napoli E, et al. **Effect of night time-intervals, height of traps**

457   **and lunar phases on sand fly collection in a highly endemic area for canine**

458   **leishmaniasis.** *Acta Trop* 2014; 133: 73–77.

459   36 Pennisi MG, Venza M, Reale S, et al. **Case report of leishmaniasis in four**

460   **cats.** *Vet Res Commun* 2004; 28: 363–366.

461   37 Richter M, Schaarschmidt-Kiener D and Krudewig C. **Ocular signs, diagnosis and**

462   **long-term treatment with allopurinol in a cat with leishmaniasis.** *Schweiz Arch*

463   *Tierheilkd* 2014; 156: 289–294.

464   38 Pimenta P, Alves-Pimenta S, Barros J, et al. **Feline leishmaniosis in Portugal: 3**

465   **cases (year 2014).** *Vet Parasitol Reg Stud Reports* 2015; 1–2: 65–69.

466   39 Solano-Gallego L, Koutinas A, Miró G, et al. **Directions for the diagnosis, clinical**

467   **staging, treatment and prevention of canine leishmaniosis.** *Vet Parasitol*

468   2009; 165: 1–18.

469   40 Marcos R, Santos M, Malhão F, et al. **Pancytopenia in a cat with visceral**

470   **leishmaniasis.** *Vet Clin Pathol* 2009; 38: 201–205.

471   41 Navarro J A, Sánchez J, Peñafiel-Verdú C, et al. **Histopathological lesions in 15**

472   **cats with leishmaniosis.** *J Comp Pathol* 2010; 143: 297–302.

Table 1. Descriptive statistics and prevalence (%) of infection among the cats included in the study groups

Variables	Total	Positive Leishmania (PL) group	Negative Leishmania (NL) group	P value	Unconfirmed Leishmania (UL) group
n	152	19	106		27
Sex					
Male	75 (49.3)	13 (68.4)	49 (46.2)	0.125*	13 (48.1)
Intact	10 (6.5)	1 (5.3)	6 (5.7)	0.322†	3 (11.1)
Castrated	65 (42.8)	12 (63.1)	43 (40.5)		10 (37)
Female	77 (50.7)	6 (31.6)	57 (53.8)		14 (51.9)
Intact	16 (10.6)	1 (5.3)	12 (11.3)		3 (11.1)
Spayed	61 (40.1)	5 (26.3)	45 (42.5)		11 (40.8)
Age (months)					
Kittens <6	4 (2.6)	0 (0)	3 (2.8)	0.755	1 (3.7)
Young 6–24	13 (8.6)	2 (10.5)	11 (10.4)		0 (0)
Adult >24	135 (88.8)	17 (89.5)	92 (86.8)		26 (96.3)
Breed					
European	128 (84.2)	14 (73.7)	92 (86.8)	0.263	22 (81.5)
Pedigree	24 (15.8)	5 (26.3)	14 (13.2)		5 (18.5)
Geographical origin					
Bologna	133 (87.5)	16 (84.2)	93 (87.7)	0.570	24 (88.9)
Modena	5 (3.3)	0 (0)	4 (3.8)		1 (3.7)
Ravenna	5 (3.3)	1 (5.3)	3 (2.8)		1 (3.7)
Ferrara	6 (3.9)	2 (10.5)	4 (3.8)		0 (0)
Forlì-Cesena	3 (2)	0 (0)	2 (1.9)		1 (3.7)
Lifestyle					
Indoor/outdoor	74 (48.7)	12 (63.29)	47 (44.3)	0.190	15 (55.6)
Indoor	63 (41.4)	7 (36.8)	49 (46.2)		7 (25.9)
NA	15 (9.9)	0 (0)	10 (9.5)		5 (18.5)
Month of sampling					
June	13 (8.6)	1 (5.3)	10 (9.4)	0.071	2 (7.4)
July	35 (23)	5 (26.3)	26 (24.5)		4 (14.8)
August	22 (14.5)	7 (36.8)	11 (10.4)		4 (14.8)
September	24 (15.8)	2 (10.5)	14 (13.2)		8 (29.6)
October	16 (10.5)	1 (5.3)	13 (12.3)		2 (7.4)

November	42 (27.6)	3 (15.8)	32 (30.2)		7 (26)

The χ2 test was carried out on the PL and NL groups

*P value referred to male/female

[†]P value referred to male (intact or castrated)/female (intact or spayed)

478 Table 2. Results obtained using the indirect immunofluorescence antibody test (IFAT)

479 and qPCR in blood, conjunctival swabs and hair samples

IFAT	Sample tested (n)	Positive	Negative	Unconfirmed
n	152	18	107	27
Median and range		1:80 (1:80–1:320)	0 (0)	1:40 (1:40)
qPCR	**Sample tested (n)**	**Positive**	**Negative**	**Quantity**
Blood	146	0	146	–
Conjunctival swabs	150	0	150	–
Hair	150	1	149	8 copies DNA/µl

480 IFAT = indirect immunofluorescence antibody test; qPCR = real-time polymerase chain
481 reaction

482 Table 3. Prevalence (%) of *Leishmania* species infection in cats detected by IFAT

Variables	IFAT			
	1:80	1:160	1:320	Total
	(n = 11)	(n = 5)	(n = 2)	(n = 18)
Sex				
Male	8 (72.7)	3 (60)	1 (50)	12 (66.7)
Intact	1 (9.1)	0 (0)	0 (0)	1 (5.6)
Castrated	7 (63.6)	3 (60)	1 (50)	11 (61.1)
Female	3 (27.3)	2 (40)	1 (50)	6 (33.3)
Intact	0 (0)	0 (0)	1 (50)	1 (5.6)
Spayed	3 (27.3)	2 (40)	0 (0)	5 (27.7)
Age (months)				
Kitten <6	0 (0)	0 (0)	0 (0)	0 (0)
Young 6–24	0 (0)	1 (20)	1 (50)	2 (11.1)
Adult >24	11 (100)	4 (80)	1 (50)	16 (88.9)
Breed				
European	10 (90.9)	3 (60)	0 (0)	13 (72.2)
Pedigree	1 (9.1)	2 (40)	2 (100)	5 (27.8)
Geographical origin				
Bologna	10 (90.9)	5 (100)	1 (50)	16 (88.9)
Modena	0 (0)	0 (0)	0 (0)	0 (0)
Ravenna	0 (0)	0 (0)	0 (0)	0 (0)
Ferrara	1 (9.1)	0 (0)	1 (50)	2 (11.1)
Forlì-Cesena	0 (0)	0 (0)	0 (0)	0 (0)
Lifestyle				
Indoor/Outdoor	7 (63.6)	4 (80)	1 (50)	12 (66.7)
Indoor	4 (36.4)	1 (20)	1 (50)	6 (33.3)
NA	0 (0)	0 (0)	0 (0)	0 (0)
Month of sampling				
June	1 (9.1)	0 (0)	0 (0)	1 (5.6)
July	2 (18.2)	1 (20)	2 (100)	5 (27.7)
August	3 (27.2)	3 (60)	0 (0)	6 (33.3)
September	2 (18.2)	0 (0)	0 (0)	2 (11.1)
October	1 (9.1)	0 (0)	0 (0)	1 (5.6)
November	2 (18.2)	1 (20)	0 (0)	3 (16.7)

483   IFAT = indirect immunofluorescence antibody test

484   Table 4. Clinicopathological results of the cats included in the PL and NL groups

Variables	Negative *Leishmania* (NL) group (n = 106)	Positive *Leishmania* (PL) group (n = 19)	Reference interval	*P v*alue
Haematology				
RBCs (cells/mm^3)	7,449,504.95 ± 2,268,986.283	7,473,333.333 ± 2,055,798.113	7,000,000–11,000,000	0.962
WBCs (cells/mm^3)	10,200 (950–77,480)	10,545 ± 4195.617	4800–14,930	0.705
Hb (fl)	10.974 ± 3.288	11.3 (7–15.2)	10–16	0.879
Hct (g%)	32.202 ± 9.517	34.6 (32.35–44.1)	32–48	0.982
MCV (fl)	43.1 (32.5–56.9)	43.667 ± 4.047	36–55	0.810
MCH (pg)	14.7 (10.8–19.7)	14.689 ± 1.578	12.3–16.2	0.672
MCHC (g%)	34.1 (31.8–46.9)	33.606 ± 1.143	31–36	0.259
MPV (fl)	16.8 (9.2–32.1)	17.683 ± 5.385	8–26	0.727
RDW (%)	15 (12.7–27.1)	15.367 ± 1.843	13.17–17	0.781
Platelets (cells/mm^3)	217,000 (1000–644,000)	252,277.8 ± 148,734.6	150,000–500,000	0.609
Reticulocytes (cells/mm^3)	33,000 (2200–162,100)	28,077.78 ± 14,184.48	0–80,000	0.106
Neutrophils (cells/mm^3)	7110 (390–76,050)	7943.333 ± 4175.889	1600–10,000	0.807
Monocytes (cells/mm^3)	230 (30–7670)	255 (60–920)	0–650	0.940
Lymphocytes (cells/mm^3)	1560 (40–17,270)	1817.222 ± 820.701	900–5600	0.750
Basophils (cells/mm^3)	10 (0–900)	10 (0–40)	0–60	0.096

Eosinophil (cells/mm^3)	290 (0–2430)	499.412 ± 399.585	60–1470	0.439
Serum Chemistry				
ALT (U/l)	64 (3–743)	60.211 ± 38.125	20–72	0.060
AST (U/l)	39 (16–828)	29 (16–115)	9–40	0.050
ALP (U/l)	25 (5–97,772)	15 (4–133)	0–140	0.009
GGT (U/l)	0.1 (0–5.2)	0.1 (0–1.4)	0–4	0.256
Total Bilirubin (mg/dl)	0.18 (0.01–20.85)	0.195 (0.04–3.23)	0–0.3	0.544
Cholesterol (mg/dl)	159.786 ± 52.549	150.5 (72–325)	64–229	0.775
Glucose (mg/dl)	127 (57–591)	121.316 ± 34.041	63–148	0.114
Albumin (g/dl)	3.023 ± 0.502	3.012 ± 0.537	2.6–4	0.997
Total Protein (g/dl)	7.171 ± 0.897	7.933 ± 0.946	6.5–8.8	0.005
A:G (g:g)	0.758 ± 0.191	0.654 ± 0.206	0.52–1.19	0.051
Creatinine (mg/dl)	1.54 (0.41–11.77)	1.71 (0.78–31.46)	0.8–1.8	0.375
Urea (mg/dl)	62.95 (12.6–533.05)	58.52 (26.3–599.85)	30–65	0.773
Phosphate (mg/dl)	4.835 (1.77–15.76)	5.05 (3.37–15.22)	2.5–6.2	0.547
Potassium (mEq/l)	4.25 (2.6–7.4)	4.363 ± 0.585	3.4–5.1	0.418
Sodium (mEq/l)	151.5 (136–168)	151.211 ± 4.454	145–155	0.720
Chloride (mEq/l)	117.000 (96.500–126.800)	116.050 ± 4.119	110–123	0.561
Magnesium (mg/dl)	2.31 (1.52–4.63)	2.466 ± 0.332	1.9–2.8	0.259
Total Calcium (mg/dl)	9.8 (6.7–13.14)	9.822 ± 0.734	8.5–10.5	0.948

SAA (μg/dl)	8 (1–308)	12 (1–202)	0–10	0.724
Serum protein electrophoresis				
Albumin (g/dl)	2.802 ± 0.607	2.912 ± 0.655	2.10–3.30	0.443
Albumin (%)	39.274 ± 7.635	37.205 ± 9.395	–	0.492
Alfa(α)$_1$-globulin (g/dl)	1.180 (0.02–3.62)	1.16 (0.09–1.63)	0.1–0.8	0.710
α_1-globulin (%)	16.3 (0.2–53.6)	14.9 (1.1–20)	–	0.057
α_2-globulin (g/dl)	0.825 (0.33–2.87)	0.81 (0.61–3.3)	0.58–1.05	0.573
α_2-globulin (%)	11.65 (5.6–39)	10.3 (7.4–39.9)	–	0.557
Beta(β)$_1$-globulin (g/dl)	0.560 (0.21–1.29)	0.587 ± 0.122	0.45–0.80	0.507
β_1-globulin (%)	8 (2.9–20.2)	7.458 ± 1.636	–	0.183
β_2-globulin (g/dl)	0.43 (0.14–1.66)	0.55 (0.32–1.21)	0.35–0.75	0.013
β_2-globulin (%)	6.25 (2.1–24.8)	7.132 ± 1.988	–	0.143
Gamma(γ)-globulin (g/dl)	1.03 (0.02–2.79)	1.37 (0.82–3.44)	0.60–1.30	0.003
γ-globulin (%)	14.85 (0.4–33.1)	20.132 ± 7.221	–	0.014
A:G (g:g)	0.672 ± 0.204	0.625 ± 0.230	–	0.489
Urinalysis				
USG	1026 (1008–1084)	1038.75 ± 23.344	>1040	0.428
Urine creatinine (mg/dl)	105.26 (13.7–436.98)	246.207 ± 186.088	–	0.042
Urine protein (mg/dl)	45.94 (2.28–2188)	93.61 (8.19–564.52)	0–0.4	0.114

UPC (mg:mg)	0.354 (0.041–38.582)	0.281 (0.115–10.631)	<0.2	0.750

485 A:G = albumin to globulin ratio; ALP = alkaline phosphatase level; ALT = alanine aminotransferase; AST = aspartate aminotransferase;

486 GGT = gamma(γ)-glutamyl transferase; Hb = hemoglobin; Hct = hematocrit value; MCH = mean corpuscular haemoglobin; MCHC =

487 mean corpuscular haemoglobin concentration; MCV = mean corpuscular volume; MPV = mean platelet volume; RBCs = red blood cells;

488 RDW = red cell distribution width; SAA = serum amyloid A; UPC = urine protein:creatinine ratio; USG = urine specific gravity; WBCs =

489 white blood cells